Lipert Maya P, Rodríguez-Hornedo Naír
Department of Pharmaceutical Sciences, University of Michigan , Ann Arbor, Michigan 48109-1065, United States.
Mol Pharm. 2015 Oct 5;12(10):3535-46. doi: 10.1021/acs.molpharmaceut.5b00111. Epub 2015 Aug 28.
In this manuscript we bring together concepts that are relevant to the solubilization and thermodynamic stability of cocrystals in the presence of drug solubilizing agents. Simple equations are derived that allow calculation of cocrystal solubilization and transition point solubility. Analysis of 10 cocrystals in 6 different solubilizing agents shows that cocrystal solubilization is quantitatively predicted from drug solubilization. Drug solubilizing agents such as surfactants and lipid-based media are also shown to induce cocrystal transition points, where drug and cocrystal solubilities are equal, and above which the cocrystal solubility advantage over drug is eliminated. We have discovered that cocrystal solubility at the transition point (S*) is independent of solubilizing agent, and can be predicted from knowledge of only the aqueous solubilities of drug and cocrystal. For 1:1 cocrystals, S* = (Scocrystal,aq)(2)/Sdrug,aq. S* is a key indicator of cocrystal thermodynamic stability and establishes the upper solubility limit below which cocrystal is more soluble than the constituent drug. These findings have important implications to tailor cocrystal solubility and stability in pharmaceutical formulations from commonly available drug solubility descriptors.
在本论文中,我们汇集了与药物增溶剂存在下共晶体的溶解及热力学稳定性相关的概念。推导了简单的方程,可用于计算共晶体的溶解及转变点溶解度。对6种不同增溶剂中的10种共晶体进行分析表明,共晶体的溶解可根据药物的溶解情况进行定量预测。表面活性剂和脂质基介质等药物增溶剂也显示可诱导共晶体转变点,即药物和共晶体溶解度相等的点,高于该点,共晶体相对于药物的溶解度优势消失。我们发现,转变点处的共晶体溶解度(S*)与增溶剂无关,仅根据药物和共晶体的水溶解度即可预测。对于1:1共晶体,S* = (Scocrystal,aq)(2)/Sdrug,aq。S*是共晶体热力学稳定性的关键指标,并确定了共晶体比其组成药物更易溶解的溶解度上限。这些发现对于根据常用的药物溶解度描述符来调整药物制剂中共晶体的溶解度和稳定性具有重要意义。